NASDAQ:NVCT Nuvectis Pharma (NVCT) Stock Price, News & Analysis $18.66 +0.64 (+3.52%) As of 10:11 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nuvectis Pharma Stock (NASDAQ:NVCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nuvectis Pharma alerts:Sign Up Key Stats Today's Range$18.10▼$19.4050-Day Range$9.31▼$28.5352-Week Range$5.55▼$29.27Volume16,124 shsAverage Volume156,654 shsMarket Capitalization$495.18 millionP/E RatioN/ADividend YieldN/APrice Target$35.00Consensus RatingHold Company Overview Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake. The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders. Lead candidates are being evaluated for inherited conditions characterized by enzyme deficiencies or receptor dysfunction, with the goal of delivering active protein payloads directly to affected cells. In parallel, the company is exploring applications of its delivery technology in areas such as oncology and inflammatory disease, seeking strategic partnerships to advance select programs into later clinical development. Headquartered in San Diego, California, Nuvectis Pharma operates with a management team drawn from established life-science and pharmaceutical backgrounds. The company maintains research collaborations with academic centers and contract development organizations to accelerate its discovery and development activities. With a focus on rare diseases and high-unmet-need patient populations, Nuvectis is positioning its platform to address therapeutic challenges that extend beyond the reach of conventional biologic and small-molecule approaches. AI Generated. May Contain Errors. Read More Nuvectis Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreNVCT MarketRank™: Nuvectis Pharma scored higher than 69% of companies evaluated by MarketBeat, and ranked 211th out of 840 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingHold Consensus RatingNuvectis Pharma has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialNuvectis Pharma has a consensus price target of $35.00, representing about 87.5% upside from its current price of $18.67.Amount of Analyst CoverageNuvectis Pharma has only been the subject of 3 research reports in the past 90 days.Read more about Nuvectis Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Nuvectis Pharma are expected to grow in the coming year, from ($0.96) to ($0.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvectis Pharma is -14.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvectis Pharma is -14.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvectis Pharma has a P/B Ratio of 25.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Nuvectis Pharma's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.51% of the float of Nuvectis Pharma has been sold short.Short Interest Ratio / Days to CoverNuvectis Pharma has a short interest ratio ("days to cover") of 2.29, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nuvectis Pharma has recently increased by 14.90%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNuvectis Pharma does not currently pay a dividend.Dividend GrowthNuvectis Pharma does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A Search Interest1 people have searched for NVCT on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Nuvectis Pharma to their MarketBeat watchlist in the last 30 days. Company Ownership5.0 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Nuvectis Pharma in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $1,166,000.00 in company stock, which represents 0.2355% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Nuvectis Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,166,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders28.55% of the stock of Nuvectis Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.77% of the stock of Nuvectis Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nuvectis Pharma's insider trading history. Receive NVCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvectis Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NVCT Stock News HeadlinesNuvectis Pharma’s NXP900 Combo Trial Adds Fresh Momentum to NVCT in EGFR Lung CancerJuly 9, 2026 | tipranks.comThe Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold RushJuly 9, 2026 | markets.businessinsider.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.July 21 at 1:00 AM | Paradigm Press (Ad)Nuvectis Pharma (NASDAQ:NVCT) CEO Buys 12,500 SharesJuly 2, 2026 | insidertrades.comNuvectis: 'Hold' On NXP800 Removal And Newly Licensed CandidatesJuly 1, 2026 | seekingalpha.comNuvectis Pharma shares slide after pricing $100 million discounted stock offering (NVCT)June 30, 2026 | finance.yahoo.comNuvectis Pharma Prices $100 Million Underwritten Public Offering of Common StockJune 29, 2026 | quiverquant.comQNuvectis Pharma Announces Pricing of $100 Million Public Offering of Common StockJune 29, 2026 | globenewswire.comSee More Headlines NVCT Stock Analysis - Frequently Asked Questions How have NVCT shares performed this year? Nuvectis Pharma's stock was trading at $7.55 at the beginning of 2026. Since then, NVCT shares have increased by 147.2% and is now trading at $18.6650. How were Nuvectis Pharma's earnings last quarter? Nuvectis Pharma, Inc. (NASDAQ:NVCT) posted its quarterly earnings results on Tuesday, May, 5th. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.04. When did Nuvectis Pharma IPO? Nuvectis Pharma (NVCT) raised $19 million in an initial public offering (IPO) on Friday, February 4th 2022. The company issued 3,200,000 shares at a price of $5.00-$7.00 per share. How do I buy shares of Nuvectis Pharma? Shares of NVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nuvectis Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvectis Pharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Invesco QQQ (QQQ), Tesla (TSLA), Meta Platforms (META), JPMorgan Chase & Co. (JPM) and Netflix (NFLX). Company Calendar Last Earnings5/05/2026Today7/21/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1d) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 NVCT's financial health is in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NVCT CIK1875558 Webwww.nuvectis.com Phone201-614-3150FaxN/AEmployees8Year Founded2020Price Target and Rating Average Price Target for Nuvectis Pharma$35.00 High Price Target$39.00 Low Price Target$33.00 Potential Upside/Downside+87.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.44 million Net MarginsN/A Pretax MarginN/A Return on Equity-161.00% Return on Assets-98.88% Debt Debt-to-Equity RatioN/A Current Ratio2.27 Quick Ratio2.27 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.72 per share Price / Book25.92Miscellaneous Outstanding Shares26,530,000Free Float18,953,000Market Cap$495.18 million OptionableNot Optionable Beta-0.24 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:NVCT) was last updated on 7/21/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredElon’s new "tollbooth"The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...Weiss Ratings | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectis Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
